To evaluate HCC cell survival by inhibiting the menin-MLL1 interaction without requiring a complete KO of the MEN1 gene, we utilized the publicly available small molecule SNDX-5613 (revumenib). This evidence concerns the gene KMT2A and hepatocellular carcinoma.